Glenn D Francis
Overview
Explore the profile of Glenn D Francis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torlakovic E, Cheung C, DArrigo C, Dietel M, Francis G, Gilks C, et al.
Appl Immunohistochem Mol Morphol
. 2017 Feb;
25(3):151-159.
PMID: 28187030
Validation of immunohistochemistry (IHC) assays is a subject that is of great importance to clinical practice as well as basic research and clinical trials. When applied to clinical practice and...
2.
Torlakovic E, Cheung C, DArrigo C, Dietel M, Francis G, Gilks C, et al.
Appl Immunohistochem Mol Morphol
. 2017 Feb;
25(2):79-85.
PMID: 28182587
All laboratory tests have test performance characteristics (TPCs), whether or not they are explicitly known to the laboratorian or the pathologist. TPCs are thus also an integral characteristic of immunohistochemistry...
3.
Cheung C, DArrigo C, Dietel M, Francis G, Fulton R, Gilks C, et al.
Appl Immunohistochem Mol Morphol
. 2016 Dec;
25(4):227-230.
PMID: 27941560
The numbers of diagnostic, prognostic, and predictive immunohistochemistry (IHC) tests are increasing; the implementation and validation of new IHC tests, revalidation of existing tests, as well as the on-going need...
4.
Cheung C, DArrigo C, Dietel M, Francis G, Gilks C, Hall J, et al.
Appl Immunohistochem Mol Morphol
. 2016 Dec;
25(1):4-11.
PMID: 27922482
Technical progress in immunohistochemistry (IHC) as well as the increased utility of IHC for biomarker testing in precision medicine avails us of the opportunity to reassess clinical IHC as a...
5.
Morey A, Brown B, Farshid G, Fox S, Francis G, McCue G, et al.
Pathology
. 2016 Aug;
48(6):535-42.
PMID: 27567228
Appropriate and accurate determination of HER2 status in women with breast cancer is critical for stratifying anti-HER2 therapies, and for access to subsidised treatment in the Australian setting. We conducted...
6.
Stirzaker C, Zotenko E, Song J, Qu W, Nair S, Locke W, et al.
Nat Commun
. 2015 Feb;
6:5899.
PMID: 25641231
Epigenetic alterations in the cancer methylome are common in breast cancer and provide novel options for tumour stratification. Here, we perform whole-genome methylation capture sequencing on small amounts of DNA...
7.
Plant H, Kashyap A, Manton K, Hollier B, Hurst C, Stein S, et al.
BMC Cancer
. 2014 Aug;
14:627.
PMID: 25167778
Background: Cancer metastasis is the main contributor to breast cancer fatalities as women with the metastatic disease have poorer survival outcomes than women with localised breast cancers. There is an...
8.
Bilous M, Morey A, Armes J, Bell R, Button P, Cummings M, et al.
Breast Cancer Res Treat
. 2012 Jun;
134(2):617-24.
PMID: 22678156
In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be...
9.
Peters K, Edwards S, Nair S, French J, Bailey P, Salkield K, et al.
BMC Cancer
. 2012 Apr;
12:132.
PMID: 22471922
Background: Breast cancer outcome, including response to therapy, risk of metastasis and survival, is difficult to predict using currently available methods, highlighting the urgent need for more informative biomarkers. Androgen...
10.
Fox S, Kumarasinghe M, Armes J, Bilous M, Cummings M, Farshid G, et al.
Am J Surg Pathol
. 2012 Feb;
36(4):577-82.
PMID: 22314190
Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HER2)-amplified/overexpressed advanced gastric and gastroesophageal junction cancers (GC/GJCs). However, the optimal method for testing is unclear....